nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomethadyl Acetate—CHRNB4—Nicotine Activity on Chromaffin Cells—CACNA1C—attention deficit hyperactivity disorder	0.0841	0.1	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Nicotine Activity on Chromaffin Cells—CACNA1C—attention deficit hyperactivity disorder	0.0769	0.0919	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Highly sodium permeable acetylcholine nicotinic receptors—CHRNA4—attention deficit hyperactivity disorder	0.0505	0.0604	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Highly sodium permeable acetylcholine nicotinic receptors—CHRNA4—attention deficit hyperactivity disorder	0.0462	0.0552	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA4—attention deficit hyperactivity disorder	0.0413	0.0494	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA4—attention deficit hyperactivity disorder	0.0378	0.0452	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA4—attention deficit hyperactivity disorder	0.0352	0.0421	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Presynaptic nicotinic acetylcholine receptors—CHRNA4—attention deficit hyperactivity disorder	0.0328	0.0392	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA4—attention deficit hyperactivity disorder	0.0322	0.0385	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Presynaptic nicotinic acetylcholine receptors—CHRNA4—attention deficit hyperactivity disorder	0.03	0.0359	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Acetylcholine Binding And Downstream Events—CHRNA4—attention deficit hyperactivity disorder	0.029	0.0347	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Acetylcholine Binding And Downstream Events—CHRNA4—attention deficit hyperactivity disorder	0.0266	0.0317	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Nicotine Activity on Dopaminergic Neurons—CHRNA4—attention deficit hyperactivity disorder	0.0192	0.0229	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Nicotine Activity on Dopaminergic Neurons—DRD3—attention deficit hyperactivity disorder	0.0173	0.0206	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Nicotine Activity on Dopaminergic Neurons—DRD4—attention deficit hyperactivity disorder	0.0168	0.02	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Nicotine Activity on Dopaminergic Neurons—DRD2—attention deficit hyperactivity disorder	0.0156	0.0187	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—forebrain—attention deficit hyperactivity disorder	0.0148	0.113	CbGeAlD
Levomethadyl Acetate—CHRNB4—nervous system—attention deficit hyperactivity disorder	0.0131	0.1	CbGeAlD
Levomethadyl Acetate—CHRNB4—central nervous system—attention deficit hyperactivity disorder	0.0126	0.0962	CbGeAlD
Levomethadyl Acetate—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRQ—attention deficit hyperactivity disorder	0.0105	0.0125	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—brain—attention deficit hyperactivity disorder	0.01	0.0764	CbGeAlD
Levomethadyl Acetate—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRQ—attention deficit hyperactivity disorder	0.00956	0.0114	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—forebrain—attention deficit hyperactivity disorder	0.00902	0.0688	CbGeAlD
Levomethadyl Acetate—CHRNA3—nervous system—attention deficit hyperactivity disorder	0.00804	0.0613	CbGeAlD
Levomethadyl Acetate—CHRNB4—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.00786	0.00939	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—central nervous system—attention deficit hyperactivity disorder	0.00774	0.059	CbGeAlD
Levomethadyl Acetate—CYP19A1—forebrain—attention deficit hyperactivity disorder	0.00758	0.0578	CbGeAlD
Levomethadyl Acetate—CHRNA3—cerebellum—attention deficit hyperactivity disorder	0.00756	0.0577	CbGeAlD
Levomethadyl Acetate—CHRNA3—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.00719	0.00858	CbGpPWpGaD
Levomethadyl Acetate—Phenoxybenzamine—ADRA2C—attention deficit hyperactivity disorder	0.00654	0.206	CrCbGaD
Levomethadyl Acetate—CHRNA3—brain—attention deficit hyperactivity disorder	0.00614	0.0469	CbGeAlD
Levomethadyl Acetate—CHRNB4—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00602	0.00719	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—midbrain—attention deficit hyperactivity disorder	0.00596	0.0454	CbGeAlD
Levomethadyl Acetate—CHRNA3—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00551	0.00658	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—FSH signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00537	0.00642	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00491	0.00586	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—nervous system—attention deficit hyperactivity disorder	0.0049	0.0374	CbGeAlD
Levomethadyl Acetate—OPRM1—central nervous system—attention deficit hyperactivity disorder	0.00471	0.036	CbGeAlD
Levomethadyl Acetate—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—attention deficit hyperactivity disorder	0.0046	0.0055	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00422	0.00504	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—attention deficit hyperactivity disorder	0.00421	0.00503	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—nervous system—attention deficit hyperactivity disorder	0.00411	0.0314	CbGeAlD
Levomethadyl Acetate—CHRNB4—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00402	0.0048	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—central nervous system—attention deficit hyperactivity disorder	0.00396	0.0302	CbGeAlD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00392	0.00469	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00392	0.00469	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—brain—attention deficit hyperactivity disorder	0.00374	0.0286	CbGeAlD
Levomethadyl Acetate—CHRNA3—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00368	0.00439	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.00358	0.00427	CbGpPWpGaD
Levomethadyl Acetate—Propiomazine—DRD4—attention deficit hyperactivity disorder	0.00346	0.109	CrCbGaD
Levomethadyl Acetate—CHRNB4—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00346	0.00413	CbGpPWpGaD
Levomethadyl Acetate—Modafinil—SLC6A3—attention deficit hyperactivity disorder	0.00344	0.108	CrCbGaD
Levomethadyl Acetate—CHRNB4—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00322	0.00384	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00316	0.00378	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—brain—attention deficit hyperactivity disorder	0.00314	0.024	CbGeAlD
Levomethadyl Acetate—CHRNB4—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00308	0.00368	CbGpPWpGaD
Levomethadyl Acetate—Benzphetamine—SLC6A3—attention deficit hyperactivity disorder	0.00298	0.0936	CrCbGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00295	0.00353	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00294	0.00351	CbGpPWpGaD
Levomethadyl Acetate—Propiomazine—DRD1—attention deficit hyperactivity disorder	0.00293	0.0921	CrCbGaD
Levomethadyl Acetate—Benzphetamine—ADRA2A—attention deficit hyperactivity disorder	0.00292	0.0918	CrCbGaD
Levomethadyl Acetate—CHRNB4—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.00287	0.00342	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00285	0.0034	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00282	0.00337	CbGpPWpGaD
Levomethadyl Acetate—Phenoxybenzamine—ADRA2A—attention deficit hyperactivity disorder	0.00279	0.0877	CrCbGaD
Levomethadyl Acetate—CHRNB4—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00265	0.00317	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.00262	0.00313	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00246	0.00294	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.00244	0.00291	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00242	0.0029	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00242	0.00289	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00241	0.00287	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.0024	0.00287	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00238	0.00285	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00226	0.0027	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00225	0.00269	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.00223	0.00266	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00223	0.00266	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00221	0.00264	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.0022	0.00262	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00218	0.00261	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00217	0.00259	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00207	0.00247	CbGpPWpGaD
Levomethadyl Acetate—Propiomazine—DRD2—attention deficit hyperactivity disorder	0.00207	0.065	CrCbGaD
Levomethadyl Acetate—CHRNA3—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00201	0.0024	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00199	0.0152	CbGeAlD
Levomethadyl Acetate—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00192	0.0147	CbGeAlD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00191	0.00228	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00187	0.00223	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00187	0.00223	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00185	0.00221	CbGpPWpGaD
Levomethadyl Acetate—Promethazine—DRD2—attention deficit hyperactivity disorder	0.00174	0.0547	CrCbGaD
Levomethadyl Acetate—CHRNA3—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00171	0.00204	CbGpPWpGaD
Levomethadyl Acetate—CHRNA3—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.0017	0.00203	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00163	0.00195	CbGpPWpGaD
Levomethadyl Acetate—Propiomazine—HTR2A—attention deficit hyperactivity disorder	0.0016	0.0502	CrCbGaD
Levomethadyl Acetate—OPRM1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00151	0.00181	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.0015	0.00179	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00145	0.00173	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.00142	0.0017	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00142	0.0017	CbGpPWpGaD
Levomethadyl Acetate—Promethazine—HTR2A—attention deficit hyperactivity disorder	0.00135	0.0423	CrCbGaD
Levomethadyl Acetate—OPRM1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00132	0.00158	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0013	0.00155	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.00128	0.00153	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00128	0.00152	CbGpPWpGaD
Levomethadyl Acetate—CHRNB4—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.00127	0.00152	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00127	0.00151	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.00126	0.00151	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00126	0.0015	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.00124	0.00149	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00123	0.00147	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00122	0.00146	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00119	0.00142	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00117	0.0014	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00116	0.00138	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00115	0.00138	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00113	0.00135	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00111	0.00133	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00111	0.00132	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.0011	0.00131	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00109	0.0013	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00108	0.00129	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00105	0.00126	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00102	0.00122	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.001	0.0012	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000989	0.00118	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000986	0.00118	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000922	0.0011	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000862	0.00103	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000821	0.00098	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000804	0.000961	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000801	0.000957	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.0008	0.000956	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000795	0.000949	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000789	0.000943	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000776	0.000927	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000763	0.000911	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000754	0.0009	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000753	0.0009	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000745	0.00089	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00073	0.000872	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000702	0.000838	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000696	0.000831	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000656	0.000784	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000646	0.000771	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000607	0.000725	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000557	0.000666	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000521	0.000623	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000512	0.000612	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000506	0.000605	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000492	0.000587	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000487	0.000582	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000453	0.000541	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000453	0.000541	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000442	0.000528	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00044	0.000526	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000439	0.000524	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000431	0.000515	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000431	0.000515	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000426	0.000509	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000423	0.000505	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000411	0.000491	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000398	0.000476	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000397	0.000474	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000392	0.000468	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000387	0.000462	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000372	0.000445	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00037	0.000441	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000367	0.000438	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00036	0.00043	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00036	0.00043	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00036	0.00043	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000354	0.000423	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000329	0.000393	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000327	0.000391	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000313	0.000373	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000313	0.000373	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000308	0.000367	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000299	0.000357	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000288	0.000344	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000286	0.000342	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000278	0.000332	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000274	0.000327	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000261	0.000312	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000252	0.000301	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00025	0.000299	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000243	0.00029	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000238	0.000284	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000235	0.000281	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000231	0.000276	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000228	0.000273	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000226	0.00027	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000226	0.00027	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000222	0.000266	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000218	0.000261	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000217	0.000259	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000213	0.000254	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00021	0.000251	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000207	0.000247	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	0.000189	0.000226	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000188	0.000225	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000181	0.000216	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000172	0.000205	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000152	0.000182	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000149	0.000178	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	0.000137	0.000164	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000136	0.000162	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000105	0.000125	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000105	0.000125	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000103	0.000123	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.61e-05	0.000115	CbGpPWpGaD
Levomethadyl Acetate—CYP19A1—Metabolism—EP300—attention deficit hyperactivity disorder	9.35e-05	0.000112	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.4e-05	0.0001	CbGpPWpGaD
Levomethadyl Acetate—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	8.12e-05	9.7e-05	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.99e-05	9.55e-05	CbGpPWpGaD
Levomethadyl Acetate—OPRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.9e-05	9.43e-05	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	6.36e-05	7.6e-05	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	6.32e-05	7.55e-05	CbGpPWpGaD
Levomethadyl Acetate—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	5.87e-05	7.01e-05	CbGpPWpGaD
Levomethadyl Acetate—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	2.73e-05	3.26e-05	CbGpPWpGaD
